Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation

Junichiro Sageshima, Gaetano Ciancio, Linda J Chen, Takehiko Dohi, Ashraf El-Hinnawi, Siegfredo Paloyo, Ryosuke Misawa, Obi Ekwenna, Ashanga Yatawatta, George W Burke

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The efficacy and safety of everolimus (EVR) in simultaneous pancreas and kidney transplantation (SPKT) is unclear. We retrospectively evaluated 25 consecutive SPKT recipients at our center from November 2011 to March 2013. All patients received dual induction (Thymoglobulin/basiliximab) and low-dose tacrolimus plus corticosteroids. Nine patients who received EVR were compared with 14 patients who received enteric-coated mycophenolate sodium (EC-MPS); two patients who received sirolimus were excluded from the analysis. With a median follow-up of 14 months, the pancreas graft survival rate was 100% in both groups, and the kidney graft survival rate was 100% and 93% in EVR and EC-MPS patients, respectively. One EC-MPS patient lost her kidney graft from proteinuric kidney disease. Another EC-MPS patient received treatment for clinically diagnosed pancreas and kidney graft rejection. No rejection was observed in EVR patients. Serum creatinine and HbA1c levels were similar between the groups. There was no significant difference of surgical or medical complications. In conclusion, EVR seems to provide comparable short-term outcome to EC-MPS when combined with low-dose tacrolimus/steroids and dual induction therapy. A larger study with a longer follow-up is required to further assess this combination.

Original languageEnglish
Pages (from-to)797-801
Number of pages5
JournalClinical Transplantation
Volume28
Issue number7
DOIs
StatePublished - Jan 1 2014

Fingerprint

Pancreas Transplantation
Tacrolimus
Kidney Transplantation
Mycophenolic Acid
Graft Survival
Kidney
Pancreas
Survival Rate
Everolimus
Graft Rejection
Kidney Diseases
Sirolimus
Creatinine
Adrenal Cortex Hormones
Steroids
Transplants
Safety
Therapeutics

Keywords

  • Everolimus
  • Kidney transplantation
  • mTOR inhibitors
  • Mycophenolate sodium
  • Pancreas transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation. / Sageshima, Junichiro; Ciancio, Gaetano; Chen, Linda J; Dohi, Takehiko; El-Hinnawi, Ashraf; Paloyo, Siegfredo; Misawa, Ryosuke; Ekwenna, Obi; Yatawatta, Ashanga; Burke, George W.

In: Clinical Transplantation, Vol. 28, No. 7, 01.01.2014, p. 797-801.

Research output: Contribution to journalArticle

Sageshima, J, Ciancio, G, Chen, LJ, Dohi, T, El-Hinnawi, A, Paloyo, S, Misawa, R, Ekwenna, O, Yatawatta, A & Burke, GW 2014, 'Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation', Clinical Transplantation, vol. 28, no. 7, pp. 797-801. https://doi.org/10.1111/ctr.12381
Sageshima, Junichiro ; Ciancio, Gaetano ; Chen, Linda J ; Dohi, Takehiko ; El-Hinnawi, Ashraf ; Paloyo, Siegfredo ; Misawa, Ryosuke ; Ekwenna, Obi ; Yatawatta, Ashanga ; Burke, George W. / Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation. In: Clinical Transplantation. 2014 ; Vol. 28, No. 7. pp. 797-801.
@article{1ad9b4f3712e4e4c824e9cfe3295c37d,
title = "Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation",
abstract = "The efficacy and safety of everolimus (EVR) in simultaneous pancreas and kidney transplantation (SPKT) is unclear. We retrospectively evaluated 25 consecutive SPKT recipients at our center from November 2011 to March 2013. All patients received dual induction (Thymoglobulin/basiliximab) and low-dose tacrolimus plus corticosteroids. Nine patients who received EVR were compared with 14 patients who received enteric-coated mycophenolate sodium (EC-MPS); two patients who received sirolimus were excluded from the analysis. With a median follow-up of 14 months, the pancreas graft survival rate was 100{\%} in both groups, and the kidney graft survival rate was 100{\%} and 93{\%} in EVR and EC-MPS patients, respectively. One EC-MPS patient lost her kidney graft from proteinuric kidney disease. Another EC-MPS patient received treatment for clinically diagnosed pancreas and kidney graft rejection. No rejection was observed in EVR patients. Serum creatinine and HbA1c levels were similar between the groups. There was no significant difference of surgical or medical complications. In conclusion, EVR seems to provide comparable short-term outcome to EC-MPS when combined with low-dose tacrolimus/steroids and dual induction therapy. A larger study with a longer follow-up is required to further assess this combination.",
keywords = "Everolimus, Kidney transplantation, mTOR inhibitors, Mycophenolate sodium, Pancreas transplantation",
author = "Junichiro Sageshima and Gaetano Ciancio and Chen, {Linda J} and Takehiko Dohi and Ashraf El-Hinnawi and Siegfredo Paloyo and Ryosuke Misawa and Obi Ekwenna and Ashanga Yatawatta and Burke, {George W}",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/ctr.12381",
language = "English",
volume = "28",
pages = "797--801",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation

AU - Sageshima, Junichiro

AU - Ciancio, Gaetano

AU - Chen, Linda J

AU - Dohi, Takehiko

AU - El-Hinnawi, Ashraf

AU - Paloyo, Siegfredo

AU - Misawa, Ryosuke

AU - Ekwenna, Obi

AU - Yatawatta, Ashanga

AU - Burke, George W

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The efficacy and safety of everolimus (EVR) in simultaneous pancreas and kidney transplantation (SPKT) is unclear. We retrospectively evaluated 25 consecutive SPKT recipients at our center from November 2011 to March 2013. All patients received dual induction (Thymoglobulin/basiliximab) and low-dose tacrolimus plus corticosteroids. Nine patients who received EVR were compared with 14 patients who received enteric-coated mycophenolate sodium (EC-MPS); two patients who received sirolimus were excluded from the analysis. With a median follow-up of 14 months, the pancreas graft survival rate was 100% in both groups, and the kidney graft survival rate was 100% and 93% in EVR and EC-MPS patients, respectively. One EC-MPS patient lost her kidney graft from proteinuric kidney disease. Another EC-MPS patient received treatment for clinically diagnosed pancreas and kidney graft rejection. No rejection was observed in EVR patients. Serum creatinine and HbA1c levels were similar between the groups. There was no significant difference of surgical or medical complications. In conclusion, EVR seems to provide comparable short-term outcome to EC-MPS when combined with low-dose tacrolimus/steroids and dual induction therapy. A larger study with a longer follow-up is required to further assess this combination.

AB - The efficacy and safety of everolimus (EVR) in simultaneous pancreas and kidney transplantation (SPKT) is unclear. We retrospectively evaluated 25 consecutive SPKT recipients at our center from November 2011 to March 2013. All patients received dual induction (Thymoglobulin/basiliximab) and low-dose tacrolimus plus corticosteroids. Nine patients who received EVR were compared with 14 patients who received enteric-coated mycophenolate sodium (EC-MPS); two patients who received sirolimus were excluded from the analysis. With a median follow-up of 14 months, the pancreas graft survival rate was 100% in both groups, and the kidney graft survival rate was 100% and 93% in EVR and EC-MPS patients, respectively. One EC-MPS patient lost her kidney graft from proteinuric kidney disease. Another EC-MPS patient received treatment for clinically diagnosed pancreas and kidney graft rejection. No rejection was observed in EVR patients. Serum creatinine and HbA1c levels were similar between the groups. There was no significant difference of surgical or medical complications. In conclusion, EVR seems to provide comparable short-term outcome to EC-MPS when combined with low-dose tacrolimus/steroids and dual induction therapy. A larger study with a longer follow-up is required to further assess this combination.

KW - Everolimus

KW - Kidney transplantation

KW - mTOR inhibitors

KW - Mycophenolate sodium

KW - Pancreas transplantation

UR - http://www.scopus.com/inward/record.url?scp=84903778543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903778543&partnerID=8YFLogxK

U2 - 10.1111/ctr.12381

DO - 10.1111/ctr.12381

M3 - Article

VL - 28

SP - 797

EP - 801

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 7

ER -